Showing 4761-4770 of 9717 results for "".
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- New Colorescience, Aesthetics Biomedical Collabhttps://practicaldermatology.com/news/new-colorescience-aesthetics-biomedical-collab/2461177/Colorescience and Aesthetics Biomedical are launching a collaboration that combines Vivace Microneedle RF with a post-treatment protocol featuring Colorescience’s Sunforgettable Total Protection Brush-On Shield SPF 50. Patients opting for the radiofrequency microneedlin
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Blueberry Extract May Improve Wound Healinghttps://practicaldermatology.com/news/blueberry-extract-may-improve-wound-healing/2461152/Treating wounds with an extract taken from wild blueberries may improve healing, according to a new study presented at the American Physiological Society’s annual meeting at Experimental Biology 2022. Researchers from the University of Maine previously found that a phenolic extrac
- DERMWIRE Exclusive: FDA Clears Cutera’s AviClear Acne Devicehttps://practicaldermatology.com/news/dermwire-exclusive-fda-clears-cuteras-aviclear-acne-device/2461124/The U.S. Food and Drug Administration has cleared granted 510(k) clearance to Cutera’s AviClear acne device. This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne. AviClear targets acne at the source by selec
- Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301https://practicaldermatology.com/news/jeune-aesthetics-announces-positive-clinical-phase-1-efficacy-results-for-kb301/2461119/Aesthetics, Inc.’s KB301 demonstrated promise in proof-of-concept in the Phase 1 PEARL-1 study. Specifically, Cohort 2 of this trial evaluated KB301 for the improvement of fine lines and skin texture in the lower and upper cheek, and for improvement in skin thickness in
- Cynosure Partners with Jeisys Medical Japanhttps://practicaldermatology.com/news/cynosure-partners-with-jeisys-medical-japan/2461114/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- P&G Ventures Reintroduces Bodewell Line for Eczema and Psoriasishttps://practicaldermatology.com/news/pg-ventures-reintroduces-bodewell-line-for-eczema-and-psoriasis/2461098/P&G Ventures is reintroducing Bodewell, a line of skin care products for people with eczema and psoriasis. Bodewell’s new eczema and psoriasis lines feature actives like Colloidal Oatmeal and Salicylic Acid along with essential moisturizers and a novel botanical blend ca
- AbbVie, University of Toronto Establish Endowed Chair in Ethnodermatologyhttps://practicaldermatology.com/news/abbvie-university-of-toronto-establish-endowed-chair-in-ethnodermatology/2461081/AbbVie donated CDN $3M to establish an AbbVie Chair in Ethnodermatology at the University of Toronto’s Temerty Faculty of Medicine. One of the first positions of its kind in the world, the Chair will drive collaborative academic research, provide advanc
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor